Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The safety and efficacy of tagraxofusp for the treatment of BPDCN

Marco Herling • 12 Jun 2022
EHA 2022
Blastic Plasmacytoid Dendritic Cell Neoplasm Leukemia Rare Diseases Tagraxofusp

Marco Herling, MD, University of Leipzig, Leipzig, Germany shares some insights into a retrospective analysis investigating the safety and efficacy of tagraxofusp for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Dr Herling first highlights the importance of increasing awareness and improving treatment options for patients with BPDCN and also discusses the promising results observed with the use of tagraxofusp. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Marco Herling

Unmet needs in BPDCN: CNS involvement & the importance of intrathecal chemotherapy prophylaxis
1:00
Unmet needs in BPDCN: CNS involvement & the importance of intrathecal chemotherapy prophylaxis
Marco Herling • 25 Apr 2023
Improvements in the awareness and diagnosis of BPDCN
1:41
Improvements in the awareness and diagnosis of BPDCN
Marco Herling • 25 Apr 2023
Managing patients with transplant-ineligible BDPCN with tagraxofusp
1:15
Managing patients with transplant-ineligible BDPCN with tagraxofusp
Marco Herling • 25 Apr 2023
The challenge of relapse in transplant-eligible & transplant-ineligible patients with BDPCN
1:23
The challenge of relapse in transplant-eligible & transplant-ineligible patients with BDPCN
Marco Herling • 25 Apr 2023

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals